LDX
LUMOS DIAGNOSTICS HOLDINGS LIMITED
$0.0930
▼ -5.10%
Market cap
$90M
Turnover
$177,378
Last price
$0.0930
Day change
-5.10%
Announcements
13
Range, past year
Open 0.175 · Low 0.024 · Now 0.093 · High 0.335
Open LDX in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
LDX momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
18/100
Wyckoff phase
Downtrend10d
Trend stage
Breakdown
1 Day
-5.1%
1 Week
-15.5%
1 Month
-7.0%
1 Year
-46.9%
RSI
40
Avg daily range
8.1%
LUMOS DIAGNOSTICS HOLDINGS LIMITED scores 18 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 10 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -28.5%
- High volatility (ATR 8.1%)
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsLDX announcements
Recent price-sensitive releases.
- 2026-09-15 FebriDx Commercial Traction Continues Across US Accounts Progress Report
- 2026-08-26 FY26 Full Year Results Announcement Preliminary Final Report | Periodic Reports - Other
- 2026-08-26 FY26 Appendix 4E Preliminary Final Report
- 2026-08-04 Lumos Receives FebriDx Order from PHASE Scientific Progress Report
- 2026-07-27 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Web Cast | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-21 FebriDx Commercial Traction Across Priority US Accounts
- 2026-06-29 Lumos Receives Research & Development Tax Rebate
More Health Care stocks
Most traded in the same sector.